- May 11, 2018
The Case for a Daily Self-Injection to Treat Hemophilia
We spoke to Nassim Usman, CEO of Catalyst, about the company’s approach to hemophilia, how its drugs work, and why he believes his company’s pipeline may provide better alternatives for hemophilia patients.
- May 3, 2018
Samumed CMO Hopes To Reach Drug Approvals Via The Wnt Pathway
The clinical-stage biotech has diverse pipeline generated by its Wnt signalling pathway technology platform, and aims to get its first drug to market in 2020.
- April 19, 2018
“This is the First Time CAR-T Has Ever Worked on Acute Myeloid Leukemia“
Celyad has reported clinical results showing the first time a patient has fully recovered from acute myeloid leukemia thanks to a CAR-T therapy, and without the need for chemotherapy preconditioning.
- April 19, 2018
Bloomberg Markets: ICO Compliance, Drug Development
Amit Munshi President/CEO Arena Pharmaceuticals Inc Discussing drug development in ulcerative colitis space.
- April 17, 2018
Arena CEO: We have two great assets and are trying to build a company around that
Looking at the performance of Arena Pharmaceuticals with CEO Amit Munshi and CNBC’s Meg Tirrell.
- April 12, 2018
Orchard Gains GSK’S Rare Disease Gene Therapy Portfolio
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it will divest its rare disease gene therapy portfolio, including Strimvelis, to Orchard Therapeutics Ltd. (London, U.K.).
- April 12, 2018
UK gene therapy firm Orchard plans stock offer after GSK deal
Britain’s Orchard Therapeutics, which has already raised more than $140 million to fund its work in gene therapy, plans another private sale of shares following its acquisition of a portfolio of GlaxoSmithKline…
- April 9, 2018
OSE Immunotherapeutics Adds Boehringer Ingelheim To Its Pharma Partnering List
Collaborating with the German family-controlled drug maker on OSE’s novel checkpoint inhibitor aligns with French firm’s strategy of partnering its portfolio candidates.
